GNMSF — GENMAB A/S
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1434265 ·
Last close
$249.00
Market Cap
$15.29B
52W High
$298.38
52W Low
$232.34
ADV30
3,360
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 896,000,000 | 831,000,000 | 225,000,000 | 53,000,000 | 12,376,000,000 | 1,521,000,000 | 6,694,000,000 |
| Dec 2025 | 1,058,000,000 | 977,000,000 | 243,000,000 | 31,000,000 | 12,873,000,000 | 1,715,000,000 | 7,026,000,000 |
| Sep 2025 | 1,022,000,000 | 964,000,000 | 459,000,000 | 401,000,000 | 7,021,000,000 | 1,761,000,000 | 1,270,000,000 |
| Jun 2025 | 925,000,000 | 868,000,000 | 360,000,000 | 336,000,000 | 6,464,000,000 | 1,296,000,000 | 1,162,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,186,000,000
Investing CF
$-5,643,000,000
Financing CF
$4,789,000,000
CapEx
$-55,000,000
Dividends Paid
—
Buybacks
$-430,000,000
EPS Diluted TTM
$11.39
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$4,098,000,000
Inventory
$18,000,000
Receivables
$1,152,000,000
ST Investments
$0
EBIT TTM
$1,265,000,000
Pretax Income TTM
$1,204,000,000
Interest Exp TTM
$61,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,900,999,936
EBITDA
$1,330,000,000
Free Cash Flow
$830,374,976
Enterprise Value
$19,110,533,120
Total Cash
$1,524,999,936
Total Debt
$5,351,000,064
Shares Out
61,393,404
Trailing EPS
$13.15
Book Value
$92.56
ROE
15.0%
ROA
8.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,720,000,000 | 1,250,000,000 | 963,000,000 | 12,873,000,000 | 7,026,000,000 | — | 1,186,000,000 |
| Dec 2024 | 3,121,000,000 | 1,015,000,000 | 1,133,000,000 | 6,414,000,000 | 1,277,000,000 | — | 1,126,000,000 |
| Dec 2023 | 2,390,000,000 | 772,000,000 | 631,000,000 | 5,232,000,000 | 545,000,000 | — | 1,071,000,000 |
| Dec 2022 | 2,087,681,170 | 901,999,165 | 784,697,534 | 4,334,978,914 | 408,324,818 | — | 563,047,827 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$13.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GMAB | GENMAB A/S | $15.40B | $25.08 | — |
| JAZZ | Jazz Pharmaceuticals plc | $14.47B | $230.56 | — |
| ASND | Ascendis Pharma A/S | $14.30B | $218.06 | — |
| AXSM | Axsome Therapeutics, Inc. | $13.13B | $255.17 | — |
| BBIO | BridgeBio Pharma, Inc. | $13.08B | $66.80 | — |
News headlines (Yahoo Finance, 1h cache)
Major Shareholder Announcement
2026-06-15 16:04 · Yahoo
Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside
2026-06-15 10:07 · Yahoo
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
2026-06-13 16:45 · Yahoo
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2026-06-11 17:17 · Yahoo
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R)
2026-06-11 14:45 · Yahoo
Truist Assigns Buy Rating to Genmab (GMAB)
2026-06-05 16:36 · Yahoo
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
2026-05-29 20:35 · Yahoo
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
2026-05-21 21:00 · Yahoo
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate
2026-05-17 00:19 · Yahoo
Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)
2026-05-13 17:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.